Piramal Pharma acquires controlling 40 per cent stake in Yapan Bio
Healthcare firm Piramal Pharma completed its purchase of an additional 40 per cent stake in CDMO Yapan Bio on 19 August 2026 to expand vaccine manufacturing
MUMBAI, India, August 19, 2026 - Piramal Pharma Ltd. has finalized its acquisition of a 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based contract development and manufacturing organization (CDMO) specializing in vaccines and biologics. The cash deal, totaling ₹76 crore ($7.95M USD), brings Piramal Pharma's ownership in Yapan Bio to 74%, effectively making Yapan Bio a subsidiary of Piramal Pharma Solutions (PPS).
The transaction, completed on August 18, 2026, is a significant step for Piramal Pharma's plan to expand its presence in the biologics sector.
With the acquisition, Piramal Pharma will integrate Yapan Bio's advanced large molecule capabilities into its service offerings, enhancing its ability to develop and scale complex biologic therapies more efficiently. Yapan Bio will continue to operate within Piramal Pharma Solutions, PPS, the CDMO arm of Piramal Pharma. The acquisition also strengthens Piramal Pharma's ADCelerate™ platform, a fixed-price, integrated service for Phase I ADC development, which can now accelerate from R&D to GMP in as little as 12 months.
Peter DeYoung, CEO of Piramal Global Pharma, stated, "This strategic investment doesn't just fuel our long-term growth; it also puts Patient Centricity into action. By integrating Yapan Bio's specialized expertise into our global network, we're empowering our partners to meet the rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need."
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
